Afamelanotide

POPULAR 2026 | RESEARCH LIBRARY

Afamelanotide

An evidence-based, plain-language information page on this specialist implant for erythropoietic protoporphyria, its melanocortin biology, research programmes and crucial distinction from tanning peptides.

Contents

What afamelanotide is

Important information and disclaimer

Approved and researched uses

Potential future uses

How it works

What evidence has found

Current regulatory and South African status

How it compares

Risks and uncertainties

Treatment and product safeguards

Common questions

Join for updates

Sources

Important information and disclaimer

This page is for general education. Afamelanotide is an authorised orphan medicine in selected jurisdictions for adults with erythropoietic protoporphyria (EPP), a rare inherited disorder causing severe phototoxic pain. Its approved product is a sterile, controlled-release subcutaneous implant inserted by a specifically trained healthcare professional. It is not an ordinary injection, tanning product, sunscreen or cosmetic treatment.

A vial, nasal spray, injectable solution or powder labelled ‘afamelanotide’, ‘Melanotan I’, ‘Scenesse’, ‘alpha-MSH analogue’ or ‘research grade’ is not equivalent to the authorised implant. Identity, stereochemistry, peptide content, purity, sterility, excipients, release profile, stability and clinical exposure may differ. SCENESSE is a brand for a specific finished implant and must not be applied to unrelated material.

Serious allergic symptoms, facial or throat swelling, breathing difficulty, collapse, a rapidly changing or suspicious pigmented skin lesion, severe implant-site infection, or an expelled or damaged implant requires prompt medical assessment. Afamelanotide does not remove the need for protective clothing, shade, light avoidance or specialist EPP and liver monitoring.

What is afamelanotide?

Afamelanotide is a synthetic 13-amino-acid analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Two substitutions and terminal modifications make it more stable and longer acting than the natural hormone. It binds predominantly to melanocortin-1 receptors (MC1R) and increases eumelanin production without requiring ultraviolet exposure.

Names and products that must not be confused

What is afamelanotide approved or researched for?

Erythropoietic protoporphyria

The current US label authorises SCENESSE to increase pain-free light exposure in adults with a history of EPP phototoxic reactions. EPP results from protoporphyrin accumulation, commonly because of ferrochelatase-pathway deficiency. Visible light can trigger severe burning pain, swelling and erythema, sometimes without the familiar appearance of sunburn. Avoidance can profoundly restrict education, work, travel and ordinary outdoor life.

Afamelanotide does not correct the underlying genetic pathway or eliminate protoporphyrin. It increases protective eumelanin and may allow more pain-free exposure. Patients must continue light-protection measures and specialist surveillance, including attention to liver disease, which is an important complication of EPP.

Other potential uses – only if future research confirms them

Afamelanotide has been studied in vitiligo together with narrow-band UVB phototherapy, xeroderma pigmentosum, polymorphic light eruption, stroke and other conditions involving pigmentation, DNA damage, inflammation or melanocortin signalling. These programmes have different biological rationales and clinical endpoints. They are investigational unless and until a regulator approves an exact product for an exact population.

A current Phase 3 record evaluates SCENESSE plus narrow-band UVB versus narrow-band UVB alone in nonsegmental vitiligo. Research in xeroderma pigmentosum asks whether melanocortin signalling can strengthen photoprotection and DNA-repair responses, but pigmentation cannot substitute for rigorous UV avoidance or cancer surveillance in this high-risk disorder.

How does afamelanotide work?

Melanocortin-1 receptor signalling

Afamelanotide binds mainly to MC1R on melanocytes. This activates cyclic-AMP signalling and promotes production of eumelanin, the brown-black pigment that absorbs and scatters light and helps neutralise reactive species. The effect is pharmacological pigmentation; it is not a physical barrier like clothing or an applied sunscreen.

Why the analogue lasts longer

Natural alpha-MSH is broken down rapidly. Afamelanotide replaces methionine with norleucine and L-phenylalanine with D-phenylalanine and has blocked termini. These changes increase enzymatic stability. The authorised polymer implant then controls release, making the dosage form central to exposure and safety.

What it does not do

Afamelanotide does not block all wavelengths, prevent every phototoxic reaction, cure EPP, remove accumulated protoporphyrin or authorise deliberate tanning. Eumelanin increase occurs independently of sun or artificial UV, so seeking extra UV exposure adds avoidable skin and eye damage rather than activating the medicine.

What has evidence found?

Pain-free light exposure

The US approval relied on randomised vehicle-controlled trials in adults with EPP. In one 180-day trial, the median total time in direct sunlight during specified hours on pain-free days was 64.1 hours with afamelanotide versus 40.5 hours with vehicle. In a 270-day trial using a narrower exposure definition, medians were 6.0 versus 0.75 hours. Different diary windows and behaviour make the results difficult to translate into a fixed number of safe minutes for an individual.

A benefit shaped by behaviour

EPP trials are unusually difficult because participants may avoid light based on lifelong fear and prior pain. More protection may not immediately produce more recorded exposure, while risk-taking changes the endpoint. Patient-reported pain-free time, quality of life, seasonal light and local climate all matter. Benefit is meaningful for a rare, disabling disease but not equivalent to unrestricted sunlight tolerance.

Safety dataset

In three US-label trials, 244 adults received afamelanotide or vehicle implants. Implant-site reactions were more common with active treatment. Nausea, fatigue, dizziness, pigmentation changes and new or darkened naevi were reported. Post-marketing serious hypersensitivity, including anaphylaxis, led to strengthened US warnings in 2024.

Evidence position in 2026

Current regulatory and South African status

Afamelanotide received European authorisation for EPP in 2014 and initial US approval in 2019. The current US SCENESSE label is for adult EPP and was revised in August 2024. It requires trained professional implantation, continued sun and light protection, monitoring after administration, and twice-yearly full-body skin examinations because existing freckles and naevi can darken and new pigmented lesions may appear.

The European indication and controlled-access conditions are also EPP-specific. Authorisation of a specialist implant does not legitimise afamelanotide vials, nasal products, tanning injections or Melanotan-labelled products. The implant is a sterile bioresorbable rod with a validated polymer release system; a compounded injection is a different dosage form and exposure.

For South Africa, no current, exact SAHPRA registration and approved professional-information record for SCENESSE or another afamelanotide product was identifiable in the public repositories during this review. Overseas approval does not establish South African registration, lawful import, supply or advertising. Any patient-access route for this rare disease requires direct confirmation with SAHPRA, the manufacturer, an EPP specialist and an authorised pharmacy.

How afamelanotide compares

Known risks and uncertainties

Commonly reported adverse reactions include implant-site bruising, discolouration, pain, itching, swelling or nodule; nausea; throat discomfort; cough; fatigue; dizziness; somnolence; skin irritation; hyperpigmentation; and melanocytic naevi. Implant expulsion can occur.

Serious hypersensitivity, urticaria, angioedema and anaphylaxis have been reported after marketing. The 2024 US label requires urgent treatment and possible implant removal when clinically necessary, followed by no further treatment after a serious reaction.

Pharmacological pigmentation can darken existing naevi and freckles and may complicate visual recognition of skin changes. The US label recommends a full-body skin examination twice yearly.

The long-term effect on melanoma and other skin-cancer risk is not fully established. Carcinogenicity studies were not conducted for the US product; clinical surveillance remains important.

The implant procedure carries risks of pain, bruising, infection, incorrect placement, expulsion and local reaction. Removal may become difficult after the bioresorbable implant begins to break down.

Renal and hepatic impairment effects on pharmacokinetics are unknown. This matters in EPP because a subset develops clinically important liver disease.

Human pregnancy and lactation data are limited, paediatric effectiveness is not established in the current US label, and older adults were underrepresented.

Changes in skin colour do not measure protection reliably. A darker appearance cannot be used to set safe light exposure or justify UV tanning.

Treatment and product safeguards

This page deliberately omits implant insertion and removal technique, personal scheduling, injection conversion and sourcing instructions. SCENESSE implantation requires manufacturer training, aseptic technique, the specified cannula, correct placement and post-procedure observation. It must not be crushed, dissolved, divided, injected from a vial or transferred into a pen or cartridge.

Assessment should confirm EPP rather than another porphyria, photosensitivity disorder or medication reaction. Specialist care may monitor blood protoporphyrin, blood counts and iron status, liver tests, gallbladder and liver complications, light exposure and quality of life. Skin surveillance and continued protective behaviour remain part of treatment.

Exact product identity is especially important because the online terms “Melanotan I” and “afamelanotide” can conceal unapproved powders of uncertain composition. A matching CAS number or sequence claim does not reproduce the sterile implant, polymer release, manufacturing controls or clinical evidence.

Common questions

Is afamelanotide a tanning peptide?

It increases eumelanin, but its authorised purpose is to increase pain-free light exposure in adults with EPP—not cosmetic tanning.

Is it the same as Melanotan II?

No. Melanotan II is a different cyclic peptide with broader receptor activity and is not an authorised substitute for SCENESSE.

Is Melanotan I the same name?

It was used historically during afamelanotide development, but an online product labelled Melanotan I is not thereby the authorised implant.

Does it cure EPP?

No. It does not correct the genetic defect or remove protoporphyrin; it provides pharmacological photoprotection.

Can patients stop using sun and light protection?

No. Current product information requires continued protective measures.

Why are skin examinations needed?

The medicine can darken existing freckles and naevi and produce pigmentation changes. Regular full-body examination helps detect suspicious lesions.

Can it be injected from a vial?

That would not be the authorised product. SCENESSE is a controlled-release, bioresorbable implant inserted by a trained professional.

Is it registered in South Africa?

No exact current SAHPRA registration was identified in the public records reviewed; access and legal status must be verified directly for the exact product.

Join for research and regulatory updates

Join the future research bulletin for EPP treatment developments, afamelanotide label changes, vitiligo and xeroderma-pigmentosum trials, safety monitoring and South African access or regulatory updates. Subscription does not provide medical advice, implants, tanning products, personal dosing or product sourcing.

Consent wording for the future form: “I agree to receive evidence and regulatory updates by email. This service does not provide medical advice, personal dosing instructions or product supply.”

Sources and further reading

US Food and Drug Administration. SCENESSE (afamelanotide) implant prescribing information, revised August 2024.

European Medicines Agency. SCENESSE European Public Assessment Report and product information.

Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine. 2015.

ClinicalTrials.gov. NCT00979745 and NCT01605136: controlled afamelanotide studies in erythropoietic protoporphyria.

ClinicalTrials.gov. NCT06109649: SCENESSE plus narrow-band UVB in nonsegmental vitiligo.

ClinicalTrials.gov. NCT05159752 and NCT05370235: afamelanotide studies in xeroderma pigmentosum.

South African Health Products Regulatory Authority. Professional-information and patient-information repositories; afamelanotide product-status search performed 7 September 2026.

British Porphyria Association and European Porphyria Network. Erythropoietic protoporphyria patient and clinical information.

Editorial method: current regulator product information, pivotal EPP trials and registered clinical-trial records were prioritised. The authorised implant was kept distinct from grey-market tanning peptides and research powders. South African status is not inferred from US or EU approval. Review after major label, trial or registration changes, and no later than March 2027.